Literature DB >> 22729482

The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas.

Jun Guo1, Chengjun Yao, Hong Chen, Dongxiao Zhuang, Weijun Tang, Guang Ren, Yin Wang, Jinsong Wu, Fengping Huang, Liangfu Zhou.   

Abstract

BACKGROUND: The marginal delineation of gliomas cannot be defined by conventional imaging due to their infiltrative growth pattern. Here we investigate the relationship between changes in glioma metabolism by proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and histopathological findings in order to determine an optimal threshold value of choline/N-acetyl-aspartate (Cho/NAA) that can be used to define the extent of glioma spread.
METHOD: Eighteen patients with different grades of glioma were examined using (1)H-MRSI. Needle biopsies were performed under the guidance of neuronavigation prior to craniotomy. Intraoperative magnetic resonance imaging (MRI) was performed to evaluate the accuracy of sampling. Haematoxylin and eosin, and immunohistochemical staining with IDH1, MIB-1, p53, CD34 and glial fibrillary acidic protein (GFAP) antibodies were performed on all samples. Logistic regression analysis was used to determine the relationship between Cho/NAA and MIB-1, p53, CD34, and the degree of tumour infiltration. The clinical threshold ratio distinguishing tumour tissue in high-grade (grades III and IV) glioma (HGG) and low-grade (grade II) glioma (LGG) was calculated.
RESULTS: In HGG, higher Cho/NAA ratios were associated with a greater probability of higher MIB-1 counts, stronger CD34 expression, and tumour infiltration. Ratio threshold values of 0.5, 1.0, 1.5 and 2.0 appeared to predict the specimens containing the tumour with respective probabilities of 0.38, 0.60, 0.79, 0.90 in HGG and 0.16, 0.39, 0.67, 0.87 in LGG.
CONCLUSIONS: HGG and LGG exhibit different spectroscopic patterns. Using (1)H-MRSI to guide the extent of resection has the potential to improve the clinical outcome of glioma surgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22729482      PMCID: PMC3407558          DOI: 10.1007/s00701-012-1418-x

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  37 in total

1.  Use of MR spectroscopy and functional imaging in the treatment planning of gliomas.

Authors:  A Narayana; J Chang; S Thakur; W Huang; S Karimi; B Hou; A Kowalski; G Perera; A Holodny; P H Gutin
Journal:  Br J Radiol       Date:  2006-10-26       Impact factor: 3.039

2.  Monoclonal antibody specific for IDH1 R132H mutation.

Authors:  David Capper; Hanswalter Zentgraf; Jörg Balss; Christian Hartmann; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-10-02       Impact factor: 17.088

3.  Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas.

Authors:  Tracy R McKnight; Kathleen R Lamborn; Tonya D Love; Mitchel S Berger; Susan Chang; William P Dillon; Andrew Bollen; Sarah J Nelson
Journal:  J Neurosurg       Date:  2007-04       Impact factor: 5.115

4.  Differential expression of angiopoietin-1 and angiopoietin-2 may enhance recruitment of bone-marrow-derived endothelial precursor cells into brain tumors.

Authors:  V Udani; J Santarelli; Y Yung; S Cheshier; A Andrews; Z Kasad; V Tse
Journal:  Neurol Res       Date:  2005-12       Impact factor: 2.448

5.  Proton magnetic resonance spectroscopic imaging in the border zone of gliomas: correlation of metabolic and histological changes at low tumor infiltration--initial results.

Authors:  Andreas Stadlbauer; Christopher Nimsky; Rolf Buslei; Katja Pinker; Stephan Gruber; Thilo Hammen; Michael Buchfelder; Oliver Ganslandt
Journal:  Invest Radiol       Date:  2007-04       Impact factor: 6.016

6.  Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas.

Authors:  Andreas Stadlbauer; Ewald Moser; Stephan Gruber; Rolf Buslei; Christopher Nimsky; Rudolf Fahlbusch; Oliver Ganslandt
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

7.  Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

Authors:  David Capper; Susanne Weissert; Jörg Balss; Antje Habel; Jochen Meyer; Diana Jäger; Ulrike Ackermann; Claudia Tessmer; Andrey Korshunov; Hanswalter Zentgraf; Christian Hartmann; Andreas von Deimling
Journal:  Brain Pathol       Date:  2009-10-27       Impact factor: 6.508

8.  Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma.

Authors:  Tejas Sankar; Zografos Caramanos; Rachid Assina; Jean-Guy Villemure; Richard Leblanc; Adrian Langleben; Douglas L Arnold; Mark C Preul
Journal:  J Neurooncol       Date:  2008-07-04       Impact factor: 4.130

9.  Detection of tumour infiltration in axonal fibre bundles using diffusion tensor imaging.

Authors:  M Schlüter; B Stieltjes; H K Hahn; J Rexilius; O Konrad-verse; H-o Peitgen
Journal:  Int J Med Robot       Date:  2005-09       Impact factor: 2.547

10.  In vivo research in astrocytoma cell proliferation with 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry.

Authors:  Jun Chen; Shu-Lan Huang; Tao Li; Xi-Lan Chen
Journal:  Neuroradiology       Date:  2006-03-22       Impact factor: 2.804

View more
  32 in total

1.  Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity.

Authors:  Hamed Akbari; Luke Macyszyn; Xiao Da; Ronald L Wolf; Michel Bilello; Ragini Verma; Donald M O'Rourke; Christos Davatzikos
Journal:  Radiology       Date:  2014-06-19       Impact factor: 11.105

2.  Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.

Authors:  James S Cordova; Hui-Kuo G Shu; Zhongxing Liang; Saumya S Gurbani; Lee A D Cooper; Chad A Holder; Jeffrey J Olson; Brad Kairdolf; Eduard Schreibmann; Stewart G Neill; Constantinos G Hadjipanayis; Hyunsuk Shim
Journal:  Neuro Oncol       Date:  2016-03-15       Impact factor: 12.300

3.  Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.

Authors:  Sarah J Nelson; Achuta K Kadambi; Ilwoo Park; Yan Li; Jason Crane; Marram Olson; Annette Molinaro; Ritu Roy; Nicholas Butowski; Soonmee Cha; Susan Chang
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

4.  Spatial Relationship of Glioma Volume Derived from 18F-FET PET and Volumetric MR Spectroscopy Imaging: A Hybrid PET/MRI Study.

Authors:  Jörg Mauler; Andrew A Maudsley; Karl-Josef Langen; Omid Nikoubashman; Gabriele Stoffels; Sulaiman Sheriff; Philipp Lohmann; Christian Filss; Norbert Galldiks; Elena Rota Kops; N Jon Shah
Journal:  J Nucl Med       Date:  2017-08-28       Impact factor: 10.057

5.  Radiomic signature of infiltration in peritumoral edema predicts subsequent recurrence in glioblastoma: implications for personalized radiotherapy planning.

Authors:  Saima Rathore; Hamed Akbari; Jimit Doshi; Gaurav Shukla; Martin Rozycki; Michel Bilello; Robert Lustig; Christos Davatzikos
Journal:  J Med Imaging (Bellingham)       Date:  2018-03-01

6.  Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.

Authors:  Cornelia Brendle; Johann-Martin Hempel; Jens Schittenhelm; Marco Skardelly; Ghazaleh Tabatabai; Benjamin Bender; Ulrike Ernemann; Uwe Klose
Journal:  Clin Neuroradiol       Date:  2017-05-09       Impact factor: 3.649

Review 7.  Precision diagnostics based on machine learning-derived imaging signatures.

Authors:  Christos Davatzikos; Aristeidis Sotiras; Yong Fan; Mohamad Habes; Guray Erus; Saima Rathore; Spyridon Bakas; Rhea Chitalia; Aimilia Gastounioti; Despina Kontos
Journal:  Magn Reson Imaging       Date:  2019-05-06       Impact factor: 2.546

8.  Malignancy probability map as a novel imaging biomarker to predict malignancy distribution: employing MRS in GBM patients.

Authors:  Manijeh Beigi; Kevan Ghasemi; Parvin Mirzaghavami; Mohammadreza Khanmohammadi; Hamidreza SalighehRad
Journal:  J Neurooncol       Date:  2018-03-14       Impact factor: 4.130

9.  Low-grade (WHO II) and anaplastic (WHO III) gliomas: differences in morphology and MRI signal intensities.

Authors:  Max-Ludwig Schäfer; Martin H Maurer; Michael Synowitz; Joost Wüstefeld; Tim Marnitz; Florian Streitparth; Edzard Wiener
Journal:  Eur Radiol       Date:  2013-05-19       Impact factor: 5.315

Review 10.  Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma.

Authors:  Janine M Lupo; Sarah J Nelson
Journal:  Semin Radiat Oncol       Date:  2014-07-26       Impact factor: 5.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.